论文部分内容阅读
目的探讨奥拉西坦联合长春西汀治疗脑梗死恢复期轻度认知功能障碍患者的临床疗效。方法选取2014年6月至2015年6月河南省滑县人民医院收治的105例梗死恢复期轻度认知功能障碍患者作为研究对象,按随机数字表法将其分为对照组(45例)和观察组(60例)。对照组患者采用长春西汀注射液进行治疗,观察组患者在对照组基础上给予奥拉西坦,比较两组患者的临床疗效、治疗前后简易智力状态检查量表(MMSE)、蒙特利尔认知评估量表(Mo CA)、圣乔治呼吸问卷(SGRQ)评分及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的MMSE、Mo CA评分均明显高于对照组,SGRQ评分明显低于对照组,差异均有统计学意义(均P<0.05)。结论奥拉西坦联合长春西汀治疗脑梗死恢复期轻度认知功能障碍患者临床疗效明显,其为一种安全有效的治疗方式,有利于提高患者的认知功能与生命质量。
Objective To investigate the clinical efficacy of oxiracetam combined with vinpocetine in the treatment of patients with mild cognitive impairment during recovery from cerebral infarction. Methods From June 2014 to June 2015, 105 patients with mild cognitive impairment at the recovery stage of the infarction in Huaxian People’s Hospital of Henan Province were selected as the research objects. According to the random number table method, they were divided into the control group (45 cases) And observation group (60 cases). Patients in the control group were treated with vinpocetine injection. The patients in the observation group were given oxiracetam on the basis of the control group. The clinical efficacy, the Mental Status Examination Scale (MMSE) before and after treatment, the Cognitive Assessment of Montreal Mo CA, St. George’s Respiratory Questionnaire (SGRQ) scores and the incidence of adverse reactions. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, MMSE and Mo CA scores of observation group were significantly higher than those of control group, and SGRQ score was significantly lower than that of control group Control group, the differences were statistically significant (P <0.05). Conclusion Oxiracetam combined with vinpocetine in patients with mild cognitive impairment during recovery from cerebral infarction has obvious curative effect, which is a safe and effective treatment, which is beneficial to improve the cognitive function and quality of life of patients.